NATCOPHARM - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 4.2
| Stock Code | NATCOPHARM | Market Cap | 16,808 Cr. | Current Price | 938 ₹ | High / Low | 1,060 ₹ |
| Stock P/E | 11.2 | Book Value | 462 ₹ | Dividend Yield | 0.64 % | ROCE | 31.8 % |
| ROE | 27.5 % | Face Value | 2.00 ₹ | DMA 50 | 920 ₹ | DMA 200 | 912 ₹ |
| Chg in FII Hold | 1.07 % | Chg in DII Hold | -0.48 % | PAT Qtr | 107 Cr. | PAT Prev Qtr | 501 Cr. |
| RSI | 48.9 | MACD | 19.0 | Volume | 7,36,948 | Avg Vol 1Wk | 7,53,050 |
| Low price | 660 ₹ | High price | 1,060 ₹ | PEG Ratio | 0.07 | Debt to equity | 0.03 |
| 52w Index | 69.6 % | Qtr Profit Var | -14.4 % | EPS | 83.8 ₹ | Industry PE | 27.2 |
📊 Natco Pharma (NATCOPHARM) offers strong fundamentals with high ROE (27.5%) and ROCE (31.8%), supported by low debt-to-equity (0.03) and attractive valuations (P/E 11.2 vs. industry 27.2). The PEG ratio of 0.07 suggests excellent growth potential relative to valuation. However, recent quarterly profit decline (-14.4%) raises caution. Technical indicators (RSI 48.9, MACD 19.0) show neutral momentum, with the stock trading slightly above both 50 DMA (920 ₹) and 200 DMA (912 ₹). The ideal entry zone for long-term investors would be ₹880–₹940. If already holding, investors should maintain a 3–5 year horizon, with partial exits near ₹1,020–₹1,060 to capture gains.
✅ Positive
- Strong ROE (27.5%) and ROCE (31.8%) highlight efficient capital use.
- Low debt-to-equity ratio (0.03) ensures financial stability.
- PEG ratio of 0.07 indicates undervaluation relative to growth.
- EPS of ₹83.8 reflects strong earnings power.
- 52-week return of 69.6% shows strong momentum.
⚠️ Limitation
- Dividend yield of 0.64% is modest.
- Quarterly profit variation (-14.4%) indicates earnings volatility.
- Stock price near upper range (₹1,060) may limit upside in short term.
📉 Company Negative News
- Quarterly PAT declined from ₹501 Cr. to ₹107 Cr.
- DII holding reduced (-0.48%), showing weaker domestic institutional support.
📈 Company Positive News
- FII holding increased (+1.07%), showing foreign investor confidence.
- Strong fundamentals with attractive valuation compared to industry peers.
- Market cap of ₹16,808 Cr. reflects solid industry presence.
🏭 Industry
- Industry P/E at 27.2 suggests peers trade at higher valuations.
- Pharma sector expected to benefit from global demand for generics and specialty drugs.
🔎 Conclusion
NATCOPHARM is a fundamentally strong pharma company with high efficiency, low leverage, and attractive valuations. Long-term investors can accumulate in the ₹880–₹940 zone for better risk-reward. Existing holders should maintain a 3–5 year horizon, with partial exits near ₹1,020–₹1,060. Despite short-term profit volatility, strong ROE, ROCE, and sector tailwinds make it a promising long-term compounder.